Ligand validation:3D20

017: (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE

017 is a Ligand Of Interest in 3D20 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
3D20_017_A_201	85%	39%	0.095	0.96	1.08	1.31	4	7	6	0	100%	0.6
4Q1Y_017_A_106	96%	23%	0.064	0.974	1.68	1.53	3	9	0	0	100%	1
2IDW_017_B_401	96%	24%	0.076	0.984	1.6	1.5	6	8	0	0	100%	0.9134
2IEN_017_B_402	95%	6%	0.075	0.979	3.3	1.8	8	16	2	0	100%	0.55
2F8G_017_B_401	94%	8%	0.072	0.972	3.03	1.67	9	13	7	0	100%	0.6
4LL3_017_A_201	93%	14%	0.079	0.975	2.09	1.78	3	10	5	0	100%	0.5
3EBZ_017_B_201	99%	37%	0.056	0.986	1.01	1.44	2	7	1	0	100%	1
5T2Z_017_B_201	94%	19%	0.078	0.977	1.76	1.7	4	13	2	0	100%	0.5

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.